Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Lanzopral

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 86Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Top US Lawyer Urges SCOTUS To Toss Amarin 's Label' Case
    Top US Lawyer Urges SCOTUS To Toss Amarin 's Label' Case

    27 Feb 2026

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/scotus-weighs-skinny-labels-top-us-lawyer-calls-toss-amarin-case-over-hikmas-vascepa-generic

    FIERCE PHARMA
    27 Feb 2026
    Share Share
    Amarin Unveils 2025 Q4 And Full-Year Financials
    Amarin Unveils 2025 Q4 And Full-Year Financials

    25 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/25/3244479/18362/en/Amarin-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html

    GLOBENEWSWIRE
    25 Feb 2026
    Share Share
    Amarin Reports Q4, FY 2025 Results, Hosts Feb. 25 Earnings Call
    Amarin Reports Q4, FY 2025 Results, Hosts Feb. 25 Earnings Call

    11 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/11/3236216/18362/en/Amarin-to-Report-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Host-Conference-Call-on-February-25-2026.html

    GLOBENEWSWIRE
    11 Feb 2026
    Share Share
    SCOTUS to hear 'skinny label' case between Amarin, Hikma
    SCOTUS to hear 'skinny label' case between Amarin, Hikma

    20 Jan 2026

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/supreme-court-agrees-review-skinny-label-battle-hikma-amarin-over-generic-vascepa

    FIERCE PHARMA
    20 Jan 2026
    Share Share
    Amarin Backs Advances in Elevated Triglyceride Therapy
    Amarin Backs Advances in Elevated Triglyceride Therapy

    09 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/09/3216008/18362/en/Amarin-Applauds-Breakthroughs-In-Therapies-For-Patients-With-Elevated-Triglycerides-Company-s-VASCEPA-VAZKEPA-Icosapent-Ethyl-Franchise-Well-Positioned-To-Benefit-Globally-From-Bro.html

    GLOBENEWSWIRE
    09 Jan 2026
    Share Share
    Amarin Announces Preliminary 2025 Financial Highlights
    Amarin Announces Preliminary 2025 Financial Highlights

    08 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/08/3215221/18362/en/Amarin-Announces-Preliminary-2025-Financial-Highlights-and-Operational-Accomplishments-Including-Achieving-Positive-Cash-Flow-Company-Well-Positioned-to-Capture-Global-Growth-Oppor.html

    GLOBENEWSWIRE
    08 Jan 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.